The type and frequency of dental diseases and disorders were determined in 162 randomly selected dogs available for necropsy. There were 82 males and 80 females ranging in age from seven months to 14 years. There were 150 purebred dogs (50 different breeds) and 12 mongrels. Only four breeds were represented by ten individuals or more: Poodles (Miniature and Toy), German Shepherds, Dachshunds, and Boxers. The oral cavity was examined macroscopically, and missing teeth, dental caries, dental calculus (tartar), and gingival epulides were recorded as to frequency and distribution. After macroscopic examination of the oral cavity, the head of each dog was sawed at the midline, fixed in formalin, and radiographed. The frequency, severity, and distribution of marginal periodontitis, periapical destruction, and root resorption were recorded. The most frequently noted disease was periodontitis, which increased in frequency and severity with increasing age of the dogs. The disease varied markedly among and within different breeds. Small dogs were more often affected with periodontitis than large dogs. Periapical destruction was a common finding. Caries and root resorption were less common. Missing teeth was a frequent disorder regardless of age. Most of the dogs had dental calculus.
In this multi-center study 38 patients with contralateral molar Class II furcation defects were treated with GTR therapy using a bioresorbable matrix barrier (test) and a nonresorbable expanded polytetrafluoroethylene (ePTFE) barrier (control). Following flap elevation, scaling, root planing, and removal of granulation tissue, each device was adjusted to cover the furcation defect. The flaps were repositioned and sutured to complete coverage of the barriers. A second surgical procedure was performed at control sites after 4 to 6 weeks to remove the nonresorbable barrier. Before treatment and 12 months postsurgery all patients were examined and probing depths, clinical attachment levels, and position of the gingival margin were recorded. The primary response variable was the change in clinical attachment level in a horizontal direction (CAL-H change). Both treatment procedures reduced the probing depths (P < or = 0.001). Statistically significant gain of clinical attachment level in both horizontal and vertical direction was found at the test sites. At control sites gain of attachment in horizontal direction was statistically significant. The gain of CAL-H was 2.2 mm at test sites compared to 1.4 mm at control sites (P < or = 0.05). At test sites, the gingival margin was maintained close to the pre-surgical level (0.3 mm), whereas at control sites gingival recession was evident (0.9 mm), the difference being statistically significant (P < or = 0.01). Postsurgical complications, such as swelling and pain were more frequent following the control treatment (P < or = 0.05).
– The effect of daily toothbrushing with 0.5 % chlorhexidine‐containing gel for 12 months was evaluated in a double‐blind study in 37 dental students. The active gel did not markedly influence plaque formation, gingival conditions, or caries as compared with placebo gel treatment. Salivary bacterial counts were performed on subgroups of six subjects using chlorhexidine gel and on six using placebo gel. No differences in the effect of treatment on the microorganisms studied in the two subgroups could be detected except for S. sanguis. The percentage of this species decreased in the placebo group and increased in the chlorhexidine group. The difference became significant after 2 weeks. A tendency to a greater reduction of S. mutans noted in the chlorhexidine group was most marked in individuals who had high initial counts of this species. The proportion of S. sanguis, which could grow on chlorhexidine‐containing mitis salivarius medium, increased and after 12 months of chlorhexidine treatment averaged 34 % of cultivable S. sanguis compared with 0.002 % prior to treatment. The number of less sensitive S. sanguis decreased in the 12 months following termination of treatment. There was no observed tendency for the selection or proliferation of other streptococci, gram‐negative rods, yeasts, or staphylococci.
In this case series study 19 Class II furcations and 47 intrabony defects in 59 patients were treated according to the principles of guided tissue regeneration using a bioresorbable matrix barrier. Gingival condition and device exposure were assessed at 2 weeks, and 1, 3, 6, and 12 months after surgery. The effect of therapy was evaluated by assessing probing depths (PD), probing attachment level (PAL), and the position of the gingival margin prior to surgery and 12 months after surgery. Mild clinical signs of inflammation in the soft tissue covering the device was found adjacent to 3 defects only and limited to the first month of healing. Device exposure occurred at 10 out of the 66 defects. At the furcation defects, the mean PD reduction amounted to 3.7 mm (P < or = 0.001). Mean gain PAL vertical was 3.4 mm and PAL horizontal 3.3 mm (P < or = 0.001), resulting in complete closure of 9 out of the 19 defects. Mean gingival recession was 0.2 mm. At the intrabony defects mean PD reduction was 5.4 mm and mean gain of PAL 4.9 mm (P < or = 0.001). Gingival recession averaged 0.5 mm (P < or = 0.05). It was concluded that the use of the matrix barrier in GTR therapy resulted in 1) reduced probing depths; 2) pronounced gain of clinical attachment; and 3) a very low incidence of gingival pathology, gingival recession, and device exposure.
Flapless transalveolar sinus lift procedures visually guided by preoperative CBCT can successfully be used to enable placement, successful healing and loading of one to three implants in residual bone height of 2.6-8.9 mm. There was no marginal bone loss during the 3-12 months follow-up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.